Adalimumab and infliximab showed the highest discontinuation rate due to patient remission, followed by golimumab, in the study of patients with rheumatoid arthritis (RA).
A large study conducted to clarify the retention rates and reasons for discontinuation of biologics for rheumatoid arthritis (RA) confirmed earlier results that infliximab and adalimumab offer the best chance for remission.
The latest results came from the Kansai Consortium for Well-Being of Rheumatic Disease patients (ANSWER), an observational multicenter registry of patients with RA in Japan’s Kansai district. This study adds to what was known previously with a larger number of treatment courses and extends the results out to 36 months to see why patients stop treatment courses of biological disease-modifying antirheumatic drugs in real-world settings.
From 2009 to 2017, 4461 patients with RA were registered and 52,654 serial disease activities were available from the database.
The 7 biologics taken by these patients comprised 4 groups: anti—tumor necrosis factor (anti-TNF) monoclonal antibodies (infliximab, adalimumab, and golimumab), soluble TNF receptor or Fab fragments against TNF (etanercept and certolizumab pegol), the fusion protein CTLA4–Ig (abatacept), and an anti–interleukin-6 agent (tocilizumab).
Adalimumab and infliximab showed the highest discontinuation rate due to patient remission, followed by golimumab.
Tocilizumab showed the lowest discontinuation rate by lack of effectiveness, and abatacept showed the lowest discontinuation rate by toxic adverse events (AEs).
Also, abatacept showed the highest overall retention rates (excluding non-toxic reasons and remission) among the 7 biologics.
The study assessed 4466 treatment courses of 2494 patients. Patients had a mean age of 57.4 years and the majority were female with a mean disease duration of 8.5 years. Their rheumatoid factor positivity was 78.6% and the disease activity score in 28 joints using erythrocyte sedimentation rate was 4.3; concomitant medications were prednisolone at a dose of 2.7 mg/day (43.1%) and methotrexate at a dose 5 mg/week (61.8%); 63.6% patients were naïve to biologics.
Treatment courses included tocilizumab (n = 895), etanercept (n = 891), infliximab (n = 748), abatacept (n = 681), adalimumab (n = 558), golimumab (n = 464), and certolizumab pegol (n = 229).
A total of 56.9% of treatment courses were stopped:
By drug, retention rates for each discontinuation reason were:
Overall retention rates, excluding non-toxic reasons and remission for discontinuation, ranged from 53.4% for infliximab to 75.5% or abatacept (P <.001).
In terms of other possible confounders, the number of previously administered biologics, concomitant corticosteroids, male sex, and higher age at baseline exhibited negative effects on total drug retention rates.
Summing up what is known about this issue so far, the authors said that abatacept and certolizumab may exhibit lower toxic AEs compared with other agents. Infliximab, adalimumab, and golimumab may have some advantages in both achieving and maintaining biologic-free remission compared with other biologics.
Reference
Ebina K, Hashimoto M, Yamamoto W, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study [published online April 11, 2019]. Arthritis Res Ther. doi: 10.1186/s13075-019-1880-4.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.